Search

The international Chi-PsoCov registry showed that biologics did not increase the risk of severe forms of COVID-19 in children with psoriasis. It was shown that COVID-19 may induce de novo psoriasis or flares of known psoriasis. We focused on children who developed a flare of psoriasis after infection, phenotypic aspects of the flares, and searched for associated factors. We included 149 children from February 2021 to May 2022 in 14 countries. The 11 who developed de novo psoriasis were excluded. We excluded 160 children (M / F = 1; mean age 12.4 years; plaque psoriasis 64.7%). Psoriasis worsened within 1 month of onset of COVID-19 in 26 cases (17.4%). For other children, psoriasis improved (n = 1; 0.6%) or remained same (n = 122; 81.9%). In 24 patients whose condition worsened, the phenotype was unchanged, and in 2, there were phenotype changes: plaque psoriasis to guttate or inverse psoriasis. Demographic characteristics, phenotype/severity of psoriasis or COVID-19 severity were not associated with flares. Only the use of systemic treatments at the time of infection protected against the occurrence of flares (50.0% vs. 27.3%, P = 0.049). In this study SARS-CoV-2 infection was associated with psoriasis flares in 17% of cases. In the majority of cases that worsened, the phenotype preceding the infection was preserved. These flares are not associated with the severity of psoriasis, severity of COVID-19 or other clinical parameters. Only systemic treatments seem to reduce this risk, probably by 'controlling' the flare. It is possible that a genetic susceptibility, not explored here, also explains this susceptibility to infection. [ABSTRACT FROM AUTHOR]